Compare ED & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ED | BDX |
|---|---|---|
| Founded | 1884 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.3B | 48.2B |
| IPO Year | 2009 | 1998 |
| Metric | ED | BDX |
|---|---|---|
| Price | $109.14 | $187.89 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 18 | 15 |
| Target Price | $108.91 | ★ $194.08 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.29% | 2.24% |
| EPS Growth | ★ 7.63 | N/A |
| EPS | ★ 2.54 | 1.59 |
| Revenue | $16,918,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $3.83 | N/A |
| Revenue Next Year | $4.93 | $2.39 |
| P/E Ratio | ★ $42.45 | $117.84 |
| Revenue Growth | ★ 10.89 | 8.24 |
| 52 Week Low | $94.96 | $140.11 |
| 52 Week High | $116.23 | $213.08 |
| Indicator | ED | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 67.48 | 62.07 |
| Support Level | $109.12 | $175.60 |
| Resistance Level | $109.49 | $192.41 |
| Average True Range (ATR) | 1.61 | 3.83 |
| MACD | 0.77 | 0.84 |
| Stochastic Oscillator | 97.40 | 91.14 |
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York, including New York City, and small parts of New Jersey. The two utilities generate nearly all of Con Ed's earnings following the sale of its clean energy business to RWE in early 2023.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.